Protagonist Therapeutics (PTGX) Accounts Payables (2015 - 2026)

Protagonist Therapeutics (PTGX) has 12 years of Accounts Payables data on file, last reported at $8.4 million in Q1 2026.

• For the quarter ending Q1 2026, Accounts Payables rose 189.24% year-over-year to $8.4 million; the trailing twelve-month figure through Mar 2026 stood at $8.4 million (up 189.24% YoY), and the FY2025 full-year result was $5.3 million, up 230.59% from the prior year.
• Accounts Payables rose to $8.4 million in Q1 2026, from $5.3 million in the prior quarter.
• In the past five years, Accounts Payables ranged from a high of $8.4 million in Q1 2026 to a low of $772000.0 in Q4 2023.
• A 5-year average of $3.8 million and a median of $3.6 million in 2024 frame the typical range for Accounts Payables.
• Peak annual rise in Accounts Payables reached 567.85% in 2022, while the deepest fall reached 82.14% in 2022.
• Tracing PTGX's Accounts Payables over 5 years: stood at $3.6 million in 2022, then slumped by 78.79% to $772000.0 in 2023, then soared by 109.2% to $1.6 million in 2024, then surged by 230.59% to $5.3 million in 2025, then jumped by 58.03% to $8.4 million in 2026.
• Business Quant data shows PTGX's Accounts Payables at $8.4 million in Q1 2026, $5.3 million in Q4 2025, and $5.6 million in Q3 2025.